BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Bortezomib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Bortezomib\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06505369-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Bortezomib: Phase 2 readout est. (NCT06505369)
DESCRIPTION:Bortezomib\, phase 2\, Multiple Myeloma.\nStudy: Bispecific T-c
 ell Redirectors as Part of First Line Treatment in Transplant Eligible Mul
 tiple Myeloma Patients\nEstimated primary completion: November 2026. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/bortezomib#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06505369
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03989414-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Bortezomib: Phase 1/2 readout est. (NCT03989414)
DESCRIPTION:Bortezomib\, phase 1/2\, Multiple Myeloma.\nStudy: A Study to D
 etermine the Recommended Dose and Regimen and to Evaluate the Safety and P
 reliminary Efficacy of CC-92480 in Combination With Standard Treatments in
  Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newl
 y Diagnosed Multiple Myeloma (NDMM)\nEstimated primary completion: 30 Nove
 mber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bortezomib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT039
 89414
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02718833-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bortezomib: Phase 2 readout est. (NCT02718833)
DESCRIPTION:Bortezomib\, phase 2\, Multiple Myeloma.\nStudy: A Study of Elo
 tuzumab With Pomalidomide\, Bortezomib\, and Dexamethasone in Relapsed Mul
 tiple Myeloma\nEstimated primary completion: December 2026. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/bortezomib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT02718833
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06029998-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bortezomib: Phase 2 readout est. (NCT06029998)
DESCRIPTION:Bortezomib\, phase 2.\nStudy: Bortezomib in Patients With Metas
 tatic Castration-Resistant Prostate Cancer With PTEN Deletion\nEstimated p
 rimary completion: December 2026. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/bortezomib#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06029998
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06342466-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bortezomib: Phase 2 readout est. (NCT06342466)
DESCRIPTION:Bortezomib\, phase 2.\nStudy: Bortezomib\, Pomalidomide\, Dexam
 ethasone for Systemic AL Amyloidosis\nEstimated primary completion: Decemb
 er 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/bortezomib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06342
 466
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05979363-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Bortezomib: Phase 2 readout est. (NCT05979363)
DESCRIPTION:Bortezomib\, phase 2.\nStudy: A Study of Bortezomib\, Lenalidom
 ide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy i
 n Transplant-Ineligible Patients With Primary Plasma Cell Leukemia\nEstima
 ted primary completion: 1 December 2026. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/bortezomib#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT05979363
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06656221-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Bortezomib: Phase 2 readout est. (NCT06656221)
DESCRIPTION:Bortezomib\, phase 2\, Mantle Cell Lymphoma.\nStudy: A Prospect
 ive\, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab
  Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Man
 tle Cell Lymphoma\nEstimated primary completion: 1 December 2026. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/bortezomib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06656221
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03729804-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20261228
DTEND;VALUE=DATE:20261229
SUMMARY:Bortezomib: Phase 3 readout est. (NCT03729804)
DESCRIPTION:Bortezomib\, phase 3\, Multiple Myeloma.\nStudy: Carfilzomib\, 
 Lenalidomide\, and Dexamethasone Versus Bortezomib\, Lenalidomide and Dexa
 methasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma 
 (COBRA)\nEstimated primary completion: 28 December 2026. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/bortezomib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT03729804
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03643549-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Bortezomib: Phase 1/2 readout est. (NCT03643549)
DESCRIPTION:Bortezomib\, phase 1/2.\nStudy: Bortezomib and Temozolomide in 
 Recurrent Grade-4 Glioma Unmethylated MGMT Promoter (BORTEM-17)\nEstimated
  primary completion: 30 December 2026. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/bortezomib#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT03643549
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01863550-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bortezomib: Phase 3 readout est. (NCT01863550)
DESCRIPTION:Bortezomib\, phase 3\, Multiple Myeloma.\nStudy: Bortezomib or 
 Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With 
 Newly Diagnosed Multiple Myeloma\nEstimated primary completion: 31 Decembe
 r 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/bortezomib#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT018635
 50
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04265872-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bortezomib: Phase 1 readout est. (NCT04265872)
DESCRIPTION:Bortezomib\, phase 1.\nStudy: Bortezomib Followed by Pembrolizu
 mab and Cisplatin in metTNBC\nEstimated primary completion: 31 December 20
 26. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/bortezomib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT04265872
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05514990-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bortezomib: Phase 1/2 readout est. (NCT05514990)
DESCRIPTION:Bortezomib\, phase 1/2\, Multiple Myeloma.\nStudy: Bortezomib a
 nd Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed 
 or Refractory Multiple Myeloma\, AMBUSH Trial\nEstimated primary completio
 n: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 bortezomib#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05514990
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03829371-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20270103
DTEND;VALUE=DATE:20270104
SUMMARY:Bortezomib: Phase 4 readout est. (NCT03829371)
DESCRIPTION:Bortezomib\, phase 4\, Multiple Myeloma.\nStudy: STUDY COMPARIN
 G TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIB
 LE POPULATION AFFECTED BY MULTIPLE MYELOMA\nEstimated primary completion: 
 3 January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/borte
 zomib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT03829371
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05519085-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20270110
DTEND;VALUE=DATE:20270111
SUMMARY:Bortezomib: Phase 3 readout est. (NCT05519085)
DESCRIPTION:Bortezomib\, phase 3\, Multiple Myeloma.\nStudy: A Study to Eva
 luate Mezigdomide\, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidom
 ide\, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or 
 Refractory Multiple Myeloma (RRMM)\nEstimated primary completion: 10 Janua
 ry 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/bortezomib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05519
 085
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04268498-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Bortezomib: Phase 2 readout est. (NCT04268498)
DESCRIPTION:Bortezomib\, phase 2\, Multiple Myeloma.\nStudy: A Study of Dar
 atumumab\, Carfilzomib\, Lenalidomide\, and Dexamethasone in Patients With
  Newly-Diagnosed Multiple Myeloma\nEstimated primary completion: 1 Februar
 y 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/bortezomib#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT042684
 98
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05736419-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20270209
DTEND;VALUE=DATE:20270210
SUMMARY:Bortezomib: Phase 2 readout est. (NCT05736419)
DESCRIPTION:Bortezomib\, phase 2.\nStudy: A Study of Immune Suppression Tre
 atment for People With Sickle Cell Disease or β-Thalassemia Who Are Going
  to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)\nEstima
 ted primary completion: 9 February 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/bortezomib#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT05736419
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04133636-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:Bortezomib: Phase 2 readout est. (NCT04133636)
DESCRIPTION:Bortezomib\, phase 2\, Multiple Myeloma.\nStudy: A Study of JNJ
 -68284528\, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Ag
 ainst B-cell Maturation Antigen (BCMA) in Participants With Multiple Myelo
 ma\nEstimated primary completion: 26 February 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/bortezomib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT04133636
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04166565-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Bortezomib: Phase 2 readout est. (NCT04166565)
DESCRIPTION:Bortezomib\, phase 2\, Multiple Myeloma.\nStudy: Daratumumab Co
 mbined With Bortezomib\, Cyclophosphamide and Dexamethasone for the Treatm
 ent of Multiple Myeloma Patients Presenting With Extramedullary Disease\nE
 stimated primary completion: March 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/bortezomib#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT04166565
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06876298-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20270325
DTEND;VALUE=DATE:20270326
SUMMARY:Bortezomib: Phase na readout est. (NCT06876298)
DESCRIPTION:Bortezomib\, phase na.\nStudy: Role of Uromodulin in Management
  of Multiple Myloma\nEstimated primary completion: 25 March 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/bortezomib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06876298
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04068597-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Bortezomib: Phase 1/2 readout est. (NCT04068597)
DESCRIPTION:Bortezomib\, phase 1/2\, Multiple Myeloma.\nStudy: Study to Eva
 luate CCS1477 (Inobrodib) in Haematological Malignancies\nEstimated primar
 y completion: 31 March 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/bortezomib#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT04068597
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02343042-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Bortezomib: Phase 1/2 readout est. (NCT02343042)
DESCRIPTION:Bortezomib\, phase 1/2\, Multiple Myeloma.\nStudy: Selinexor an
 d Backbone Treatments of Multiple Myeloma Patients\nEstimated primary comp
 letion: April 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/b
 ortezomib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT02343042
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05558319-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Bortezomib: Phase 3 readout est. (NCT05558319)
DESCRIPTION:Bortezomib\, phase 3\, Multiple Myeloma.\nStudy: NDMM Patients 
 Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iber
 domide\nEstimated primary completion: April 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/bortezomib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05558319
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03319667-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20270405
DTEND;VALUE=DATE:20270406
SUMMARY:Bortezomib: Phase 3 readout est. (NCT03319667)
DESCRIPTION:Bortezomib\, phase 3\, Multiple Myeloma.\nStudy: A Study to Inv
 estigate the Clinical Benefit of Isatuximab in Combination With Bortezomib
 \, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple 
 Myeloma Not Eligible for Transplant\nEstimated primary completion: 5 April
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/bortezomib#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0331966
 7
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04754945-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20270506
DTEND;VALUE=DATE:20270507
SUMMARY:Bortezomib: Phase 1 readout est. (NCT04754945)
DESCRIPTION:Bortezomib\, phase 1.\nStudy: Isatuximab as Upfront Therapy for
  the Treatment of High Risk AL Amyloidosis\nEstimated primary completion: 
 6 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bortezomi
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04
 754945
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04915248-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Bortezomib: Phase 2 readout est. (NCT04915248)
DESCRIPTION:Bortezomib\, phase 2.\nStudy: Study to Evaluate Combined Treatm
 ent of Daratumumab\, Bortezomib and Dexamethasone in PBL Patients.\nEstima
 ted primary completion: 1 July 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/bortezomib#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT04915248
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT00572169-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Bortezomib: Phase 3 readout est. (NCT00572169)
DESCRIPTION:Bortezomib\, phase 3\, Multiple Myeloma.\nStudy: UARK 2006-66\,
  Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy\nEstimated p
 rimary completion: August 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/bortezomib#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT00572169
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05665140-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Bortezomib: Phase 2/3 readout est. (NCT05665140)
DESCRIPTION:Bortezomib\, phase 2/3\, Multiple Myeloma.\nStudy: Expression-l
 inked and R-ISS-adapted Stratification for First Line Therapy in Multiple 
 Myeloma Patients\nEstimated primary completion: August 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/bortezomib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05665140
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03136146-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Bortezomib: Phase 2 readout est. (NCT03136146)
DESCRIPTION:Bortezomib\, phase 2.\nStudy: Combination Chemotherapy in Treat
 ing Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia\, Ly
 mphoblastic Lymphoma\, Burkitt Lymphoma/Leukemia\, or Double-Hit Lymphoma/
 Leukemia\nEstimated primary completion: 1 August 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/bortezomib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT03136146
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT00869232-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Bortezomib: Phase 2 readout est. (NCT00869232)
DESCRIPTION:Bortezomib\, phase 2\, Multiple Myeloma.\nStudy: UARK 2008-02 A
  Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Comple
 te Remission\nEstimated primary completion: October 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/bortezomib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT00869232
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03004287-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Bortezomib: Phase 2 readout est. (NCT03004287)
DESCRIPTION:Bortezomib\, phase 2\, Multiple Myeloma.\nStudy: 2015-12: A Stu
 dy Exploring the Use of Early and Late Consolidation/Maintenance Therapy\n
 Estimated primary completion: October 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/bortezomib#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT03004287
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06681922-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Bortezomib: Phase 1/2 readout est. (NCT06681922)
DESCRIPTION:Bortezomib\, phase 1/2.\nStudy: A Phase I-II Study of High-Dose
  Post-Transplant Cyclophosphamide\, Bortezomib\, and Abatacept for the Pre
 vention of Graft-Versus-Host Disease (GVHD) Following Allogeneic Hematopoi
 etic Stem Cell Transplantation (HSCT)\nEstimated primary completion: Octob
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/bortezomib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06681
 922
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07789522-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20271009
DTEND;VALUE=DATE:20271010
SUMMARY:Bortezomib: Phase 2 readout est. (NCT07789522)
DESCRIPTION:Bortezomib\, phase 2\, Multiple Myeloma.\nStudy: Safety and Eff
 icacy of Elranatamab Plus Isatuximab\, Bortezomib\, and Lenalidomide in Ul
 tra-High-Risk Multiple Myeloma\nEstimated primary completion: 9 October 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/bortezomib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07789522
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03763162-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Bortezomib: Phase 2 readout est. (NCT03763162)
DESCRIPTION:Bortezomib\, phase 2\, Multiple Myeloma.\nStudy: Daratumumab\, 
 Bortezomib\, and Dexamethasone Followed by Daratumumab\, Ixazomib\, and De
 xamethasone in Treating Patients With Relapsed or Refractory Multiple Myel
 oma\nEstimated primary completion: 30 October 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/bortezomib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT03763162
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05289167-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Bortezomib: Phase 1/2 readout est. (NCT05289167)
DESCRIPTION:Bortezomib\, phase 1/2.\nStudy: Post-Transplant Cyclophosphamid
 e\, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disea
 se (GvHD)\nEstimated primary completion: November 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/bortezomib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT05289167
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07018050-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Bortezomib: Phase 2 readout est. (NCT07018050)
DESCRIPTION:Bortezomib\, phase 2\, Multiple Myeloma.\nStudy: Phase II Study
  of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma\nEst
 imated primary completion: November 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/bortezomib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07018050
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT00871013-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Bortezomib: Phase 2 readout est. (NCT00871013)
DESCRIPTION:Bortezomib\, phase 2.\nStudy: Trial for Patients Not Qualifying
  for TT4 and TT5 Protocols Because of Prior Therapy\nEstimated primary com
 pletion: December 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/bortezomib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT00871013
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06158841-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Bortezomib: Phase 3 readout est. (NCT06158841)
DESCRIPTION:Bortezomib\, phase 3\, Multiple Myeloma.\nStudy: Study Assessin
 g Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Avail
 able Therapies in Adult Participants With Relapsed or Refractory Multiple 
 Myeloma\nEstimated primary completion: December 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/bortezomib#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06158841
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06390319-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Bortezomib: Phase 2 readout est. (NCT06390319)
DESCRIPTION:Bortezomib\, phase 2.\nStudy: Adding Dasatinib Or Venetoclax To
  Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphobla
 stic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia 
 (MPAL)\nEstimated primary completion: December 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/bortezomib#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06390319
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07297329-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Bortezomib: Phase 3 readout est. (NCT07297329)
DESCRIPTION:Bortezomib\, phase 3\, Multiple Myeloma.\nStudy: A Study to Eva
 luate the Safety and Efficacy of SCTC21C in Combination With Bortezomib\, 
 Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple M
 yeloma Not Eligible for Transplant\nEstimated primary completion: December
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/bortezomib#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0729732
 9
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07388602-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Bortezomib: Phase 3 readout est. (NCT07388602)
DESCRIPTION:Bortezomib\, phase 3.\nStudy: A Study to Evaluate the Safety an
 d Efficacy of SCTC21C in Combination With Bortezomib\, Cyclophosphamide\, 
 and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain Am
 yloidosis (NDSLCA)\nEstimated primary completion: December 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/bortezomib#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07388602
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04775550-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20271220
DTEND;VALUE=DATE:20271221
SUMMARY:Bortezomib: Phase 2 readout est. (NCT04775550)
DESCRIPTION:Bortezomib\, phase 2\, Multiple Myeloma.\nStudy: DARA RVD For H
 igh Risk SMM\nEstimated primary completion: 20 December 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/bortezomib#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT04775550
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07008638-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Bortezomib: Phase 1/2 readout est. (NCT07008638)
DESCRIPTION:Bortezomib\, phase 1/2.\nStudy: Phase I/II Clinical Trial of Pr
 oteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-
 Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)\nEstimated primary com
 pletion: 30 December 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/bortezomib#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07008638
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03590171-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Bortezomib: Phase 2 readout est. (NCT03590171)
DESCRIPTION:Bortezomib\, phase 2.\nStudy: International Study for Treatment
  of High Risk Childhood Relapsed ALL 2010\nEstimated primary completion: 3
 1 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bort
 ezomib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT03590171
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04566328-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Bortezomib: Phase 3 readout est. (NCT04566328)
DESCRIPTION:Bortezomib\, phase 3\, Multiple Myeloma.\nStudy: Testing the Us
 e of Combination Therapy in Adult Patients With Newly Diagnosed Multiple M
 yeloma\, the EQUATE Trial\nEstimated primary completion: 31 December 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/bortezomib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT04566328
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05599880-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Bortezomib: Phase 2 readout est. (NCT05599880)
DESCRIPTION:Bortezomib\, phase 2.\nStudy: The Investigate Efficacy and Safe
 ty Evaluation of Bortezomib in Patients With Relapsed/Refractory Immune Th
 rombocytopenia\nEstimated primary completion: 31 December 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/bortezomib#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT05599880
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04414475-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Bortezomib: Phase 2 readout est. (NCT04414475)
DESCRIPTION:Bortezomib\, phase 2\, Multiple Myeloma.\nStudy: A Study of Sel
 inexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple 
 Myeloma (MM)\, Seli and Bortezomib + LDD in Triple-class Refractory MM.\nE
 stimated primary completion: January 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/bortezomib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT04414475
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03850366-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Bortezomib: Phase 2 readout est. (NCT03850366)
DESCRIPTION:Bortezomib\, phase 2.\nStudy: HLA-Haploidentical Peripheral Blo
 od Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bor
 tezomib\nEstimated primary completion: 1 January 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/bortezomib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT03850366
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05272826-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Bortezomib: Phase 2 readout est. (NCT05272826)
DESCRIPTION:Bortezomib\, phase 2\, Multiple Myeloma.\nStudy: Study of Iberd
 omide\, Bortezomib\, Dexamethasone With Isatuximab Added on Demand for ND-
 NTE MM Patients\nEstimated primary completion: March 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/bortezomib#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05272826
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05137054-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20280325
DTEND;VALUE=DATE:20280326
SUMMARY:Bortezomib: Phase 1 readout est. (NCT05137054)
DESCRIPTION:Bortezomib\, phase 1\, Multiple Myeloma.\nStudy: A Study to Exa
 mine the Effects of Novel Therapy Linvoseltamab in Combination With Other 
 Cancer Treatments for Adult Participants With Multiple Myeloma That is Res
 istant to Current Standard of Care Treatments\nEstimated primary completio
 n: 25 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bor
 tezomib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05137054
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07045909-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Bortezomib: Phase 2 readout est. (NCT07045909)
DESCRIPTION:Bortezomib\, phase 2\, Multiple Myeloma.\nStudy: Efficacy and S
 afety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Mu
 ltiple Myeloma (GEM-AnitoFIRST)\nEstimated primary completion: 31 March 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/bortezomib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07045909
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07341867-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Bortezomib: Phase 1 readout est. (NCT07341867)
DESCRIPTION:Bortezomib\, phase 1\, Multiple Myeloma.\nStudy: Systemic Anti-
 Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotyp
 e\nEstimated primary completion: 31 March 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/bortezomib#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07341867
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06353022-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20280426
DTEND;VALUE=DATE:20280427
SUMMARY:Bortezomib: Phase 2 readout est. (NCT06353022)
DESCRIPTION:Bortezomib\, phase 2\, Multiple Myeloma.\nStudy: Minimal Residu
 al Disease-based Strategy With T-Cell Redirector After Treatment With Dara
 tumumab\, Bortezomib\, Lenalidomide\, and Dexamethasone (D-VRd) in Newly D
 iagnosed Multiple Myeloma\nEstimated primary completion: 26 April 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/bortezomib#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06353022
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03617731-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Bortezomib: Phase 3 readout est. (NCT03617731)
DESCRIPTION:Bortezomib\, phase 3\, Multiple Myeloma.\nStudy: Trial on the E
 ffect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Inducti
 on and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (
 GMMG HD7)\nEstimated primary completion: June 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/bortezomib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT03617731
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07334535-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Bortezomib: Phase 4 readout est. (NCT07334535)
DESCRIPTION:Bortezomib\, phase 4\, Multiple Myeloma.\nStudy: Isa-VRD in TIE
  HRMM\nEstimated primary completion: July 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/bortezomib#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07334535
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03643276-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20280714
DTEND;VALUE=DATE:20280715
SUMMARY:Bortezomib: Phase 3 readout est. (NCT03643276)
DESCRIPTION:Bortezomib\, phase 3.\nStudy: Treatment Protocol for Children a
 nd Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017\nEst
 imated primary completion: 14 July 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/bortezomib#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT03643276
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06034561-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Bortezomib: Phase 2 readout est. (NCT06034561)
DESCRIPTION:Bortezomib\, phase 2.\nStudy: Bortezomib-based Regimen for Refr
 actory or Relapsed Acute Lymphoblastic Leukemia\nEstimated primary complet
 ion: August 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bor
 tezomib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06034561
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05695508-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20280915
DTEND;VALUE=DATE:20280916
SUMMARY:Bortezomib: Phase 2 readout est. (NCT05695508)
DESCRIPTION:Bortezomib\, phase 2\, Multiple Myeloma.\nStudy: GMMG-HD10 / DS
 MM-XX / 64007957MMY2003\, MajesTEC-5\nEstimated primary completion: 15 Sep
 tember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bortezom
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5695508
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT00092222-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:Bortezomib: Phase 2 readout est. (NCT00092222)
DESCRIPTION:Bortezomib\, phase 2.\nStudy: Virotherapy and Natural History S
 tudy of KHSV-Associated Multricentric Castleman s Disease With Correlates 
 of Disease Activity\nEstimated primary completion: 1 October 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/bortezomib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT00092222
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05848687-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Bortezomib: Phase 1/2 readout est. (NCT05848687)
DESCRIPTION:Bortezomib\, phase 1/2.\nStudy: TINI 2: Total Therapy for Infan
 ts With Acute Lymphoblastic Leukemia II\nEstimated primary completion: Dec
 ember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bortezomi
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 848687
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07635511-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20290101
DTEND;VALUE=DATE:20290102
SUMMARY:Bortezomib: Phase 3 readout est. (NCT07635511)
DESCRIPTION:Bortezomib\, phase 3.\nStudy: Acalabrutinib Maleate and Bortezo
 mib for Patients With HLA Antibodies\nEstimated primary completion: 1 Janu
 ary 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bortezomib#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0763
 5511
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07085728-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20290111
DTEND;VALUE=DATE:20290112
SUMMARY:Bortezomib: Phase 2 readout est. (NCT07085728)
DESCRIPTION:Bortezomib\, phase 2\, Multiple Myeloma.\nStudy: Testing the In
 vestigational Agent Combination of Daratumumab\, Bortezomib\, and Dexameth
 asone Compared to the Usual Treatment of Cyclophosphamide\, Bortezomib\, a
 nd Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney 
 Failure\nEstimated primary completion: 11 January 2029. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/bortezomib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07085728
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07764978-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20290111
DTEND;VALUE=DATE:20290112
SUMMARY:Bortezomib: Phase 3 readout est. (NCT07764978)
DESCRIPTION:Bortezomib\, phase 3\, Multiple Myeloma.\nStudy: Study of AZD01
 20 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT\nEstimated prim
 ary completion: 11 January 2029. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/bortezomib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07764978
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04923893-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20290214
DTEND;VALUE=DATE:20290215
SUMMARY:Bortezomib: Phase 3 readout est. (NCT04923893)
DESCRIPTION:Bortezomib\, phase 3\, Multiple Myeloma.\nStudy: A Study of Bor
 tezomib\, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel\, a C
 AR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and
  Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple 
 Myeloma for Whom ASCT is Not Planned as Initial Therapy\nEstimated primary
  completion: 14 February 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/bortezomib#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT04923893
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07614360-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Bortezomib: Phase 2 readout est. (NCT07614360)
DESCRIPTION:Bortezomib\, phase 2\, Multiple Myeloma.\nStudy: Study of Alter
 native and Approved Dosing Regimens of Belantamab Mafodotin\, Bortezomib\,
  and Dexamethasone (BVd) in Participants With Relapsed/Refractory Multiple
  Myeloma\nEstimated primary completion: 28 February 2029. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/bortezomib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07614360
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07891923-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20290505
DTEND;VALUE=DATE:20290506
SUMMARY:Bortezomib: Phase 2 readout est. (NCT07891923)
DESCRIPTION:Bortezomib\, phase 2\, Multiple Myeloma.\nStudy: Less Doses of 
 Daratumumab Are Adequate to Achieve Response in Newly Diagnosed Multiple M
 yeloma\nEstimated primary completion: 5 May 2029. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/bortezomib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07891923
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07222761-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20290521
DTEND;VALUE=DATE:20290522
SUMMARY:Bortezomib: Phase 3 readout est. (NCT07222761)
DESCRIPTION:Bortezomib\, phase 3\, Multiple Myeloma.\nStudy: A Study to Com
 pare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination
  Therapy With Standard-of-Care Combination Regimens in Adult Participants 
 With Relapsed/Refractory Multiple Myeloma (RRMM)\nEstimated primary comple
 tion: 21 May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bo
 rtezomib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07222761
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07652905-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Bortezomib: Phase 2 readout est. (NCT07652905)
DESCRIPTION:Bortezomib\, phase 2.\nStudy: CM336 Plus Isa-VR in Newly Diagno
 sed Primary Plasma Cell Leukemia\nEstimated primary completion: 30 June 20
 29. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/bortezomib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07652905
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07601100-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20290701
DTEND;VALUE=DATE:20290702
SUMMARY:Bortezomib: Phase 1/2 readout est. (NCT07601100)
DESCRIPTION:Bortezomib\, phase 1/2\, Multiple Myeloma.\nStudy: Isatuximab\,
  Iberdomide\, Bortezomib\, Dexamethasone in Transplant Ineligible/Deferred
  Newly Diagnosed Myeloma\nEstimated primary completion: 1 July 2029. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/bortezomib#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07601100
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07464210-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20290801
DTEND;VALUE=DATE:20290802
SUMMARY:Bortezomib: Phase 2 readout est. (NCT07464210)
DESCRIPTION:Bortezomib\, phase 2.\nStudy: Nemtabrutinib\, Bortezomib\, and 
 Rituximab for WM\nEstimated primary completion: 1 August 2029. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/bortezomib#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07464210
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04240054-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Bortezomib: Phase 2 readout est. (NCT04240054)
DESCRIPTION:Bortezomib\, phase 2\, Multiple Myeloma.\nStudy: Bortezomib\, I
 satuximab\, Cyclophosphamide and Dexamethasone Induction in Transplant-Eli
 gible Multiple Myeloma Patients With Renal Insufficiency\nEstimated primar
 y completion: 1 December 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/bortezomib#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT04240054
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07513129-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Bortezomib: Phase 1 readout est. (NCT07513129)
DESCRIPTION:Bortezomib\, phase 1.\nStudy: Venetoclax\, Dexamethasone\, Bort
 ezomib\, and Daratumumab For The Treatment Of Adolescent And Young Adults 
 With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell
  Acute Lymphoblastic Lymphoma\nEstimated primary completion: 31 December 2
 029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/bortezomib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07513129
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07675174-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20300701
DTEND;VALUE=DATE:20300702
SUMMARY:Bortezomib: Phase 1/2 readout est. (NCT07675174)
DESCRIPTION:Bortezomib\, phase 1/2.\nStudy: PTCy\, Bortezomib and Sitaglipt
 in for Prevention of GvHD Following Allogeneic HSCT\nEstimated primary com
 pletion: 1 July 2030. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /bortezomib#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07675174
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06022939-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20300729
DTEND;VALUE=DATE:20300730
SUMMARY:Bortezomib: Phase 3 readout est. (NCT06022939)
DESCRIPTION:Bortezomib\, phase 3.\nStudy: Comparing Dara-VCD Chemotherapy P
 lus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Hav
 e Newly Diagnosed AL Amyloidosis\nEstimated primary completion: 29 July 20
 30. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/bortezomib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06022939
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227311-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20300830
DTEND;VALUE=DATE:20300831
SUMMARY:Bortezomib: Phase 2 readout est. (NCT07227311)
DESCRIPTION:Bortezomib\, phase 2\, Multiple Myeloma.\nStudy: A Study to Eva
 luate the Efficacy and Safety of Belantamab Mafodotin in Combination With 
 Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma
  (RRMM)\nEstimated primary completion: 30 August 2030. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/bortezomib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07227311
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06577025-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20300902
DTEND;VALUE=DATE:20300903
SUMMARY:Bortezomib: Phase 2 readout est. (NCT06577025)
DESCRIPTION:Bortezomib\, phase 2\, Multiple Myeloma.\nStudy: A Study of Dif
 ferent Sequences of Cilta-cel\, Talquetamab in Combination With Daratumuma
 b and Teclistamab in Combination With Daratumumab Following Induction With
  Daratumumab\, Bortezomib\, Lenalidomide and Dexamethasone in Participants
  With Standard-risk Newly Diagnosed Multiple Myeloma\nEstimated primary co
 mpletion: 2 September 2030. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/bortezomib#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06577025
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07247097-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20301201
DTEND;VALUE=DATE:20301202
SUMMARY:Bortezomib: Phase 2 readout est. (NCT07247097)
DESCRIPTION:Bortezomib\, phase 2\, Multiple Myeloma.\nStudy: ELDORADO: Elra
 natamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnose
 d Transplant Ineligible/Deferred Multiple Myeloma\nEstimated primary compl
 etion: 1 December 2030. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/bortezomib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07247097
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03314181-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20310531
DTEND;VALUE=DATE:20310601
SUMMARY:Bortezomib: Phase 2 readout est. (NCT03314181)
DESCRIPTION:Bortezomib\, phase 2\, Multiple Myeloma.\nStudy: A Study of Com
 bination Therapy With Venetoclax\, Daratumumab and Dexamethasone (With and
  Without Bortezomib) in Participants With Relapsed or Refractory Multiple 
 Myeloma\nEstimated primary completion: May 2031. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/bortezomib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT03314181
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07609706-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20310822
DTEND;VALUE=DATE:20310823
SUMMARY:Bortezomib: Phase 1 readout est. (NCT07609706)
DESCRIPTION:Bortezomib\, phase 1\, Multiple Myeloma.\nStudy: A Study of the
  Combination of Belantamab Mafodotin\, Bortezomib\, and Dexamethasone (BVd
 ) in Participants With Multiple Myeloma and Moderate Hepatic Impairment\nE
 stimated primary completion: 22 August 2031. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/bortezomib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07609706
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07285239-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20311130
DTEND;VALUE=DATE:20311201
SUMMARY:Bortezomib: Phase 3 readout est. (NCT07285239)
DESCRIPTION:Bortezomib\, phase 3\, Multiple Myeloma.\nStudy: Belantamab Maf
 odotin or Daratumumab With Bortezomib\, Lenalidomide and Dexamethasone for
  Newly Diagnosed Multiple Myeloma\nEstimated primary completion: November 
 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/bortezomib#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07285239
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07224672-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20330112
DTEND;VALUE=DATE:20330113
SUMMARY:Bortezomib: Phase 2 readout est. (NCT07224672)
DESCRIPTION:Bortezomib\, phase 2.\nStudy: A Study to Evaluate the Efficacy 
 and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide\, 
 Bortezomib\, and Dexamethasone in Adult Participants With Newly Diagnosed 
 Amyloid Light Chain (AL) Amyloidosis\nEstimated primary completion: 12 Jan
 uary 2033. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bortezomib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT072
 24672
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05257083-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20330630
DTEND;VALUE=DATE:20330701
SUMMARY:Bortezomib: Phase 3 readout est. (NCT05257083)
DESCRIPTION:Bortezomib\, phase 3\, Multiple Myeloma.\nStudy: A Study of Dar
 atumumab\, Bortezomib\, Lenalidomide and Dexamethasone (DVRd) Followed by 
 Ciltacabtagene Autoleucel Versus Daratumumab\, Bortezomib\, Lenalidomide a
 nd Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT)
  in Participants With Newly Diagnosed Multiple Myeloma\nEstimated primary 
 completion: June 2033. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/bortezomib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05257083
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07887984-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20330801
DTEND;VALUE=DATE:20330802
SUMMARY:Bortezomib: Phase 2/3 readout est. (NCT07887984)
DESCRIPTION:Bortezomib\, phase 2/3\, Multiple Myeloma.\nStudy: Comparing Bi
 specific Antibody Treatment to Autologous Stem Cell Transplant for Newly D
 iagnosed\, Standard Risk Multiple Myeloma\nEstimated primary completion: 1
  August 2033. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bortezo
 mib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07887984
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07624513-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20331001
DTEND;VALUE=DATE:20331002
SUMMARY:Bortezomib: Phase 3 readout est. (NCT07624513)
DESCRIPTION:Bortezomib\, phase 3\, Multiple Myeloma.\nStudy: D2 - Isa-Iber-
 VD Induction\, Followed by Risk & Response Adapted Consolidation & Mainten
 ance\, in Transplant-Eligible NDMM\nEstimated primary completion: 1 Octobe
 r 2033. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/bortezomib#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076245
 13
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07072585-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20350901
DTEND;VALUE=DATE:20350902
SUMMARY:Bortezomib: Phase 2/3 readout est. (NCT07072585)
DESCRIPTION:Bortezomib\, phase 2/3.\nStudy: Testing the Addition of Daratum
 umab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lym
 phoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)\nEsti
 mated primary completion: 1 September 2035. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/bortezomib#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07072585
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06918002-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20360531
DTEND;VALUE=DATE:20360601
SUMMARY:Bortezomib: Phase 3 readout est. (NCT06918002)
DESCRIPTION:Bortezomib\, phase 3\, Multiple Myeloma.\nStudy: Elranatamab/Le
 nalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of
  Care After D-VRd Induction in Transplant-eligible NDMM Patients\nEstimate
 d primary completion: May 2036. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/bortezomib#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06918002
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07600151-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20360930
DTEND;VALUE=DATE:20361001
SUMMARY:Bortezomib: Phase 1/2 readout est. (NCT07600151)
DESCRIPTION:Bortezomib\, phase 1/2\, Multiple Myeloma.\nStudy: Etenta-Isa-V
 Rd in Newly Diagnosed High-Risk Multiple Myeloma\nEstimated primary comple
 tion: 30 September 2036. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/bortezomib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07600151
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07903506-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20390331
DTEND;VALUE=DATE:20390401
SUMMARY:Bortezomib: Phase 3 readout est. (NCT07903506)
DESCRIPTION:Bortezomib\, phase 3\, Multiple Myeloma.\nStudy: To Evaluate Sa
 fety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell
  Transplant in Newly Diagnosed Multiple Myeloma\nEstimated primary complet
 ion: March 2039. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bort
 ezomib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07903506
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07887672-3125@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20420228
DTEND;VALUE=DATE:20420301
SUMMARY:Bortezomib: Phase 3 readout est. (NCT07887672)
DESCRIPTION:Bortezomib\, phase 3\, Multiple Myeloma.\nStudy: A Trial to Eva
 luate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of 
 Care in Newly Diagnosed Multiple Myeloma\nEstimated primary completion: Fe
 bruary 2042. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bortezom
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7887672
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
